Tumor avatars could personalize sarcoma therapy
NCT ID NCT07405346
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if growing a patient's tumor cells in the lab (called organoids) can help doctors choose the most effective first-line chemotherapy for advanced leiomyosarcoma, a rare cancer of smooth muscle. About 50 adults aged 18-75 who have not yet received systemic treatment will be enrolled. The main goal is to improve the tumor shrinkage rate and delay cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China